Skip to content
Triangle logo TriangleGet started
← Study library

NCT03513952 · REGISTRY CONDITION SEARCH

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2024-07-26

This phase II trial studies how well atezolizumab when given with glycosylated recombinant human interleukin-7 (CYT107) works in treating patients with urothelial carcinoma that has spread to nearby tissue or lymph nodes (locally advanced), cannot be removed by surgery (inoperable), or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. CYT107 is a biological product naturally made by the body that may stimulate the immune system to destroy tumor cells. Giving atezolizumab and CYT107 may work better in treating patients with locally advanced, inoperable, or metastatic urothelial carcinoma compared to atezolizumab alone.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Objective Response Rate (ORR)

→

outcome · POSTED

Clinical Benefit Rate (CBR) Measured by RECIST v1.1

→

outcome · POSTED

Progression-free Survival (PFS)

→

outcome · POSTED

Duration of Response (DOR)

→

outcome · POSTED

Overall Survival (OS)

→

outcome · NOT POSTED

Assessment of Investigation Treatment Combination on the Immune-bias of the Tumor Microenvironment

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Patients must have histologically or cytologically documented locally advanced/inoperable or metastatic urothelial bladder carcinoma (UBC), including renal pelvis, ureters, urinary bladder, and urethra * Note: Mixed histology tumors allowed if predominant histology is urothelial carcinoma * Note: Small cell or neuroendocrine carcinoma is not allowed if predominant * Patients must have recurrent disease after any prior platinum-based chemotherapy regimen * Patients must have measurable disease per RECIST 1.1 assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI) * ECOG performance status =\< 2 (Karnofsky \>= 60%) * Patients must have a life expectancy of greater or equal to 12 weeks * Leukocytes \>= 2,500/mcL * Absolute neutrophil count \>= 1,000/mcL * Platelets \>= 100,000/mcL * Hemoglobin \>= 8 g/dL * Total bilirubin =\< 1.5 x institutional upper limit of normal (ULN) (however, patients with known Gilbert's disease who have serum bilirubin level =\< 3 x ULN may be enrolled) * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 3 x ULN (AST and/or ALT=\< 5 x ULN for patients with liver involvement) * Alkaline phosphatase =\< 2.5 x ULN (=\< 5 x ULN for patients with documented liver involvement or bone metastases) * Creatinine clearance \>= 30 mL/min/1.73 m\^2 by Cockcroft-Gault * At the discretion of the treating physician, a 24-hour urine creatinine clearance could be obtained and utilized as the gold standard if creatinine clearance by Cockcroft-Gault is \< 30, and prevents patient enrollment on the trial * International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =\< 1.5 x ULN (this applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation, such as low-molecular-weight heparin or warfarin, should be on a stable dose) * Patients must provide tissue from an archival tumor sample (obtained within 2 years from screening visit) or newly obtained core, punch, or excisional biopsy of a tumor lesion if deemed relatively safe and technically feasible * Female patients of childbearing potential must have a negative urine or serum pregnancy test within 72 hours before receiving the first dose of study agent(s); if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; * Administration of atezolizumab may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality; CYT107 has not been tested for reproductive toxicity yet and may expose to the same risk; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) before study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of study agent; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately * Patients must have the ability to understand and the willingness to sign a written informed consent document * Patients positive for human immunodeficiency virus (HIV) are allowed on study, but HIV-positive patients must have: * A stable regimen of highly active antiretroviral therapy (HAART) * No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections * A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based tests Exclusion Criteria: * Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation * Patients who have had chemotherapy or radiotherapy within 2 weeks (4 weeks for nitrosoureas or systemic mitomycin C) before the initiation of study treatment * Patients who have received more than 2 systemic cytotoxic chemotherapy regimens for metastatic urothelial carcinoma * Note: Prior perioperative chemotherapy is allowed and is not counted as a line of therapy if patient relapsed \>= 12 months later and received additional platinum-based chemotherapy for metastatic disease * Patients who have not recovered from adverse events (other than alopecia) due to agents administered more than 4 weeks earlier (i.e., have residual toxicities \> grade 1); however, the following therapies are allowed: * Hormone-replacement therapy or oral contraceptives * Herbal therapy \>= 1 week before initiation of study treatment (herbal therapy intended as anticancer therapy must be discontinued at least 1 week before initiation of study treatment) * Palliative radiotherapy for bone metastases \> 2 weeks before initiation of study treatment * Patients who have received prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody, or pathway -targeting agents * Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met: * Minimum of 12 weeks from the first dose of anti-CTLA-4 and \> 6 weeks from the last dose * No history of severe immune-related adverse effects from anti-CTLA-4 (National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] grade 3 and 4) * Patients who have received treatment with any other investigational agent within 4 weeks before initiation of study treatment * Patients who have received treatment with systemic immunostimulatory agents (including, but not limited to, interferon \[IFN\]-alpha or interleukin \[IL\]-2) within 6 weeks before initiation of study treatment * Patients who have received treatment with systemic immunosuppressive medications (including, but not limited to, oral prednisone ( \> 10 mg/day or equivalent), cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \[anti TNF\] agents) within 2 weeks before initiation of study treatment * Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled * The use of inhaled corticosteroids, and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed * Patients taking bisphosphonate therapy for symptomatic hypercalcemia * Note: Use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed * Patients with known primary central nervous system (CNS) malignancy or symptomatic CNS metastases are excluded, with the following exceptions: * Patients with asymptomatic untreated CNS disease may be enrolled, provided all of the following criteria are met: * Evaluable or measurable disease outside the CNS * No metastases to brain stem, midbrain, pons, medulla, cerebellum, or within 10 mm of the optic apparatus (optic nerves and chiasm) * No history of intracranial hemorrhage or spinal cord hemorrhage * No ongoing requirement for dexamethasone for CNS disease; patients on a stable dose of anticonvulsants are permitted * No neurosurgical resection or brain biopsy within 28 days before initiation of study treatment * Patients with asymptomatic treated CNS metastases may be enrolled, provided all the criteria listed above are met as well as the following: * Radiographic demonstration of improvement upon the completion of CNS directed therapy and no evidence of interim progression between the completion of CNS directed therapy and the screening radiographic study * No stereotactic radiation or whole-brain radiation within 28 days before initiation of study treatment * Screening CNS radiographic study \>= 4 weeks from completion of radiotherapy and \>= 2 weeks from discontinuation of corticosteroids * Note: Patients with CNS metastases enrolled on trial must also have a brain MRI imaging at all standard radiologic evaluation timepoints * Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies * Patients who have a history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins * Patients with known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver/nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH); and inherited liver disease * Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen \[HBsAg\] test and a positive anti-HBc \[antibody to hepatitis B core antigen\] antibody test) are eligible * Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA) * Patients with active underlying autoimmune disease requiring systemic immunosuppressive medication (oral prednisone \> 10 mg/day or equivalent). Topical, inhaled, or intra-articular steroids or physiologic endocrine replacement (insulin, levothyroxine, etc.) are permitted. Patients with a history of autoimmune disease that is not currently active require consultation with the protocol principal investigator (PI) and/or Cancer Immunotherapy Trials Network (CITN) Coordinating Center * Patients who have a history of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest CT scan; history of radiation pneumonitis in the radiation field (fibrosis) is permitted * Patients who have known additional malignancies other than UBC within 2 years before initiation of study treatment; exceptions include malignancies with a negligible risk of metastasis or death and treated with expected curative outcome (e.g., non-melanomatous skin cancers), or localized prostate cancer treated with curative intent and absence of prostate-specific antigen (PSA) relapse or incidental prostate cancer * Patients with active tuberculosis (TB) * Patients who have leptomeningeal disease * Patients who have severe infections within 4 weeks before initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia; * Exception: Uncomplicated urinary tract infection will not be considered as a severe infection in these patients * Patients who have signs or symptoms of infection within 2 weeks before initiation of study treatment * Patients who have received oral or IV antibiotics within 2 weeks before initiation of study treatment; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible * Patients who have major surgical procedure, other than for diagnosis, within 28 days before initiation of study treatment or anticipation of need for a major surgical procedure during the course of the study * Patients who have had a live, attenuated vaccine within 4 weeks before initiation of study treatment or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab. * Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks before initiation of study treatment or at any time during the study * Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure (New York Heart Association class III or IV), unstable angina pectoris, cardiac arrhythmia, recent myocardial infarction (within the last 6 months), or psychiatric illness/social situations that would limit compliance with study requirements * Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or medical (e.g., infectious) illness
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive CYT107 IM on days 1, 8, 15, and 22, and atezolizumab IV over 60 minutes on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI scans, and collection of blood and stool samples on study. Patients may also undergo tumor biopsy at screening and on study.
    intervention Names
    1. Drug: Atezolizumab
    2. Procedure: Biopsy
    3. Procedure: Biospecimen Collection
    4. Procedure: Computed Tomography
    5. Biological: Glycosylated Recombinant Human Interleukin-7
    6. Other: Laboratory Biomarker Analysis
    7. Procedure: Magnetic Resonance Imaging
    8. Procedure: Positron Emission Tomography and Computed Tomography Scan
    label
    Group 1 (CYT107, atezolizumab)
    type
    EXPERIMENTAL
  2. description
    Patients receive atezolizumab IV over 60 minutes on cycle 1. Following cycle 1, patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI scans, and collection of blood and stool samples on study. Patients may also undergo tumor biopsy at screening and on study.
    intervention Names
    1. Drug: Atezolizumab
    2. Procedure: Biopsy
    3. Procedure: Biospecimen Collection
    4. Procedure: Computed Tomography
    5. Other: Laboratory Biomarker Analysis
    6. Procedure: Magnetic Resonance Imaging
    7. Procedure: Positron Emission Tomography and Computed Tomography Scan
    label
    Group 2 (atezolizumab)
    type
    ACTIVE_COMPARATOR
  3. description
    Patients assigned to the experimental arm (atezolizumab + CYT107). If the treatment combination of the experimental arm demonstrates an acceptable safety profile in the Safety Run-In (one or fewer patient experiences a protocol-defined Dose Limiting-Toxicity), randomized enrollment into the trial will begin. The Run-in phase patients will be analyzed and reported separately both for safety and for efficacy.
    intervention Names
    1. Drug: Atezolizumab
    2. Procedure: Biopsy
    3. Procedure: Biospecimen Collection
    4. Procedure: Computed Tomography
    5. Biological: Glycosylated Recombinant Human Interleukin-7
    6. Other: Laboratory Biomarker Analysis
    7. Procedure: Magnetic Resonance Imaging
    8. Procedure: Positron Emission Tomography and Computed Tomography Scan
    label
    Safety run in phase
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Group 1 (CYT107, atezolizumab)
    2. Group 2 (atezolizumab)
    3. Safety run in phase
    description
    Given IV
    name
    Atezolizumab
    other Names
    1. MPDL 3280A
    2. MPDL 328OA
    3. MPDL-3280A
    4. MPDL3280A
    5. MPDL328OA
    6. RG 7446
    7. RG-7446
    8. RG7446
    9. RO 5541267
    10. RO-5541267
    11. RO5541267
    12. Tecentriq
    type
    DRUG
  2. arm Group Labels
    1. Group 1 (CYT107, atezolizumab)
    2. Group 2 (atezolizumab)
    3. Safety run in phase
    description
    Undergo biopsy of tumor
    name
    Biopsy
    other Names
    1. BIOPSY_TYPE
    2. Bx
    type
    PROCEDURE
  3. arm Group Labels
    1. Group 1 (CYT107, atezolizumab)
    2. Group 2 (atezolizumab)
    3. Safety run in phase
    description
    Undergo collection of blood and stool samples
    name
    Biospecimen Collection
    other Names
    1. Biological Sample Collection
    2. Biospecimen Collected
    3. Specimen Collection
    type
    PROCEDURE
  4. arm Group Labels
    1. Group 1 (CYT107, atezolizumab)
    2. Group 2 (atezolizumab)
    3. Safety run in phase
    description
    Undergo CT
    name
    Computed Tomography
    other Names
    1. CAT
    2. CAT Scan
    3. Computed Axial Tomography
    4. Computerized Axial Tomography
    5. Computerized axial tomography (procedure)
    6. Computerized Tomography
    7. Computerized Tomography (CT) scan
    8. CT
    9. CT Scan
    10. tomography
    type
    PROCEDURE
  5. arm Group Labels
    1. Group 1 (CYT107, atezolizumab)
    2. Safety run in phase
    description
    Given IM
    name
    Glycosylated Recombinant Human Interleukin-7
    other Names
    1. CYT-107
    2. CYT107
    3. Glycosylated rhIL-7
    4. INTERLEUKIN-7 HUMAN RECOMBINANT
    type
    BIOLOGICAL
  6. arm Group Labels
    1. Group 1 (CYT107, atezolizumab)
    2. Group 2 (atezolizumab)
    3. Safety run in phase
    description
    Correlative studies
    name
    Laboratory Biomarker Analysis
    type
    OTHER
  7. arm Group Labels
    1. Group 1 (CYT107, atezolizumab)
    2. Group 2 (atezolizumab)
    3. Safety run in phase
    description
    Undergo MRI
    name
    Magnetic Resonance Imaging
    other Names
    1. Magnetic Resonance
    2. Magnetic Resonance Imaging (MRI)
    3. Magnetic resonance imaging (procedure)
    4. Magnetic Resonance Imaging Scan
    5. Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
    6. MR
    7. MR Imaging
    8. MRI
    9. MRI Scan
    10. MRIs
    11. NMR Imaging
    12. NMRI
    type
    PROCEDURE
  8. arm Group Labels
    1. Group 1 (CYT107, atezolizumab)
    2. Group 2 (atezolizumab)
    3. Safety run in phase
    description
    Undergo PET/CT
    name
    Positron Emission Tomography and Computed Tomography Scan
    other Names
    1. PET-CT Scan
    2. PET/CT SCAN
    3. Positron Emission Tomography/Computed Tomography
    type
    PROCEDURE
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
47
type
ACTUAL
Registered outcome plans (not posted results)
other Outcomes
  1. description
    The evaluation of the effect of the investigation treatment combination on the immune-bias of the tumor microenvironment, based upon baseline and post-baseline tumor biopsy comparisons of number, distribution, and phenotype of tumor-infiltrating cells; PD-L1 expression, and expression of Interferon gamma (IFN-gamma) and associated proinflammatory gene expression in the tumor microenvironment.
    measure
    Assessment of Investigation Treatment Combination on the Immune-bias of the Tumor Microenvironment
    time Frame
    Up to 2 years
primary Outcomes
  1. description
    ORR is defined as the proportion of patients who have achieved Complete Response (CR) - disappearance of all target lesions or Partial Response (PR) - \>=30% decrease in the sum of the longest diameter of target lesions according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; Overall Response (OR) = CR + PR.
    measure
    Objective Response Rate (ORR)
    time Frame
    Up to 2 years
secondary Outcomes
  1. description
    CBR is defined as the percentage of patients with advanced or metastatic cancer who have achieved CR (disappearance of all target lesions), PR (\>=30% decrease in the sum of the longest diameter of target lesions), and stable disease (SD) (neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum diameters of target lesions) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; CBR = CR + PR + SD. Will also assess CBR in patients stratified by PD-L1 expression levels in the tumor microenvironment.
    measure
    Clinical Benefit Rate (CBR) Measured by RECIST v1.1
    time Frame
    Up to 2 years
  2. description
    Progression is defined, per RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions (the sum must demonstrate an absolute increase of at least 5 mm), or the appearance of new lesions and/or unequivocal progression of non-target lesions. PFS will be summarized using Kaplan-Meier estimates. Will also assess PFS in patients stratified by PD-L1 expression levels in the tumor microenvironment.
    measure
    Progression-free Survival (PFS)
    time Frame
    Time from start of treatment to time of progression or death, whichever occurs first, assessed up to 2 years.
  3. description
    DOR is measured by RECIST v1.1. DOR will be summarized using Kaplan-Meier estimates. Will also assess DOR in patients stratified by PD-L1 expression levels in the tumor microenvironment.
    measure
    Duration of Response (DOR)
    time Frame
    Time interval between the date of first response (CR/PR) and the date of progression, assessed up to 2 years.
  4. description
    OS will be summarized using Kaplan-Meier estimates. Will also assess OS in patients stratified by PD-L1 expression levels in the tumor microenvironment.
    measure
    Overall Survival (OS)
    time Frame
    Time interval between start of treatment to death due to any cause, assessed up to 48 months.
Full study description
brief Summary
This phase II trial studies how well atezolizumab when given with glycosylated recombinant human interleukin-7 (CYT107) works in treating patients with urothelial carcinoma that has spread to nearby tissue or lymph nodes (locally advanced), cannot be removed by surgery (inoperable), or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. CYT107 is a biological product naturally made by the body that may stimulate the immune system to destroy tumor cells. Giving atezolizumab and CYT107 may work better in treating patients with locally advanced, inoperable, or metastatic urothelial carcinoma compared to atezolizumab alone.
detailed Description
PRIMARY OBJECTIVE: I. To determine the clinical efficacy of the investigational treatment combination. SECONDARY OBJECTIVES: I. To determine the clinical activity and toxicity of the investigational treatment combination. II. The clinical benefit rate (CBR), progression-free survival (PFS), duration of response (DOR), as measured by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and immune-related response criteria (irRC), and overall survival (OS). III. The CBR, PFS, DOR, and OS in all patients and patients stratified by PD-L1 expression levels in the tumor microenvironment. IV. The safety and toxicity of addition of CYT107 to atezolizumab. EXPLORATORY OBJECTIVES: I. To determine the immune correlates of the clinical activity of the investigational treatment combination. II. Explore the effect of the investigational treatment combination on the number and phenotype of tumor-specific T cells in the peripheral blood. III. Investigate for evidence that the investigational treatment combination increases the exposure of bladder cancer-specific antigens (e.g., cancer/testis antigens or neoantigens). IV. Investigate changes in tumor microenvironment that correlate with response or provide information on potential actionable causes for lack of clinical benefit. V. Investigate the potential that administration of atezolizumab with CYT107 may perturb the pharmacokinetics and immunogenicity of CYT107. OUTLINE: SAFETY RUN-IN PHASE: Patients assigned to the experimental arm (atezolizumab + CYT107). If the treatment combination of the experimental arm demonstrates an acceptable safety profile in the Safety Run-In (one or fewer patient experiences a protocol-defined Dose Limiting-Toxicity), randomized enrollment into the trial will begin. The Run-in phase patients will be analyzed and reported separately both for safety and for efficacy. Patients are randomized to 1 of 2 groups. GROUP 1 (experimental arm): Patients receive CYT107 intramuscularly (IM) on days 1, 8, 15, and 22, and atezolizumab intravenously (IV) over 60 minutes on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) and/or magnetic resonance imaging (MRI) scans, and collection of blood and stool samples on study. Patients may also undergo tumor biopsy at screening and on study. GROUP 2 (control arm): Patients receive atezolizumab IV over 60 minutes on cycle 1. Following cycle 1, patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI scans, and collection of blood and stool samples on study. Patients may also undergo tumor biopsy at screening and on study. After completion of study treatment, patients are followed up at 30 days and then every 12 weeks for up to 2 years.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-7f629908ad535cef62ab
      requested nct id
      NCT03513952
      primary nct id
      NCT03513952
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      308f79635904744c3081b7bece1bbf864685110f5917c0840a211e0e58d7fefc
      payload sha256
      c090dcc8753551adaab5483fb25f8424f363c129ec64f7df22664a9f8d4b38e9
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-7f629908ad535cef62ab
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT03513952
      occurrences
      1. context exact
        NCT03513952
        end
        11
        exact text
        NCT03513952
        start
        0
      offset unit
      unicode_code_points
      query cond
      Urethral Cancer
      query disease state id
      ds-urethral-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-urethral-cancer-000.json
      source file sha256
      308f79635904744c3081b7bece1bbf864685110f5917c0840a211e0e58d7fefc
      source json pointer
      /studies/34/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      b3f845af2d807328bbb6722bb802b3fe8b8fd5145f4ac21438559be37f5367e9

    Preserved source evidence · Not medical advice